We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Reports Lackluster Results From Lumakras Combo Studies
Amgen Reports Lackluster Results From Lumakras Combo Studies
Amgen’s cancer drug Lumakras (sotorasib), developed to treat KRAS G12C-mutated tumors, has posted disappointing phase 1b study results when combined with other regimens.